Allogeneic hematopoietic stem cell transplantation(allo-HSCT)is the main treatment for a variety of hematological malignancies, but chronic graft-versus-host disease(cGVHD)is subsequently a common complication. Among them, ocular graft-versus-host disease(oGVHD)is the most common one, which mainly involves lacrimal glands, eyelid glands, cornea, and conjunctiva. The typical syndrome is dry eye syndrome characterized by fibrosis. The oGVHD-related dry eye has led to a significant reduction in the quality of life of patients, which has attracted widespread attention. In addition to systemic immunosuppressant and ocular lubricants, topical corticosteroids and cyclosporine are usually used in combination for the treatment of oGVHD. Newer treatments for moderate to severe oGVHD also include the use of autologous serum eye drops and scleral contact lenses. This article mainly reviews the current treatment status of oGVHD and dry eye, with a view to provide ideas for clinical diagnosis and treatment.